Epiomic Epidemiology Series: Malignant Melanoma Forecast in 20 Major Markets 2016-2026

May 2016 | 88 pages | ID: EE8562B8B38EN
Black Swan Analysis limited

Abstracts

Cutaneous Malignant Melanoma is a form of cancer of the skin arising from melanocytes on the external surface of the skin. It can occur anywhere on the body and is more aggressive than the other two forms of skin cancer (basal cell and squamous cell non-melanoma cell skin cancer). Melanoma is the result of a combination of genetic / phenotypic predisposition and environmental catalysts.

This report provides the current incident population for Malignant Melanoma across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Sweden, Norway, Japan, China, Russia, Australia, Canada, Turkey, South Africa, Saudi Arabia, South Korea, Argentina, Brazil and Mexico) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Malignant Melanoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Malignant Melanoma include:

• Family history of Malignant Melanoma
• Atypical nevus syndrome
• Exposure to UV light
• Skin colour
• History of Sun burn
• Cutaneous reaction to sun exposure (freckling, inability to tan, sunburn tendency)
• > 50 common moles

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Malignant Melanoma’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Malignant Melanoma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Malignant Melanoma’s incident population.
• Identify sub-populations within Malignant Melanoma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Malignant Melanoma patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Malignant Melanoma Incidence
Stages and Subtype of Malignant Melanoma
  Staging of Malignant Melanoma
  Location of Malignant Melanoma
  Clark’s Subtype of Malignant Melanoma
Biomarkers and Mutations in Malignant Melanoma
  LDH Status in Stage III Malignant Melanoma
  BRAF Mutations in Malignant Melanoma
  NRAS Mutations in Malignant Melanoma
Estimates of Treatment Eligible Malignant Melanoma Patients
  Treated patients with BRAF+ Cutaneous Malignant Melanoma
  Treated patients with BRAF wild-type Cutaneous Malignant Melanoma
Abbreviations and Acronyms used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Figures

LIST OF FIGURES

Increase in cutaneous melanoma incidence by gender in the UK

List Of Tables

LIST OF TABLES

UICC/AJCC Staging for Melanoma
Clark’s Classification of Melanoma
Clark’s Subtype of Melanoma
Average survival rates for Melanoma by Breslow’s thickness
Incidence of Malignant Melanoma, total (000s)
Incidence of Malignant Melanoma, males (000s)
Incidence of Malignant Melanoma, females (000s)
AJCC staging in Malignant Melanoma patients, total (000s)
AJCC Stage III breakdown for Malignant Melanoma patients, total (000s)
Location of Malignant Melanoma, total (000s)
Clark’s Subtype of Malignant Melanoma, total (000s)
LDH Status in Stage III Malignant Melanoma, total (000s)
Malignant Melanoma with BRAF mutation, total (000s)
BRAF mutation types in Malignant Melanoma patients, total (000s)
Acral-Lentiginous Malignant Melanoma with BRAF mutation, total (000s)
Malignant Melanoma with NRAS mutation, total (000s)
NRAS mutation types in Malignant Melanoma patients, total (000s)
Treated Patients by line for Malignant Melanoma, BRAF mutation positive (000s)
Treated Patients by line for Malignant Melanoma, BRAF wild-type (000s)
Abbreviations and Acronyms used in the report
USA Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
USA Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
France Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
France Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Germany Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Germany Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Italy Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Italy Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Spain Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Spain Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Turkey Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Turkey Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Russia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Russia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Japan Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Japan Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
China Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
China Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
South Korea Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
South Korea Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Sweden Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Sweden Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Norway Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Norway Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Australia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Australia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Canada Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Canada Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Argentina Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Argentina Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Brazil Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Brazil Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Mexico Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Mexico Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
South Africa Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
South Africa Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)